Main Article Content
Botulinum toxin was first described in 1895. It is a potent neurotoxin released by clostridium, a gram-negative, anaerobic, rod-shaped bacterium. Initially, it was considered to be the cause of life-threatening disease. However, research demonstrated it to be a novel and effective therapy in managing a range of diseases, including some that affect the urinary bladder. It was approved by the Food and Drug Administration (FDA) in 1898.
This study aimed to evaluate the long-term effects of intravesical botulinum toxin A (BTA) injections in patients with an indwelling long-term catheter for detrusor overactivity. The patients selected for this study were experiencing significant catheter-associated symptoms such as bypassing, bladder spasms, intractable pain, blockages, and recurrent infections.
A retrospective cohort study was conducted in patients that received intravesical BTA after the failure of symptom management using oral anticholinergic and beta 3-adrenocepter agonist. A group of 12 patients was identified, and they were followed up in the clinic after receiving treatment.
All of the patients included in this study had relief of their symptoms following administration of intravesical BTA. Almost 58% (n = 7) of patients required 3 or fewer treatments with BTA to gain symptom control, with the remaining patients gaining control after 4 treatments. There were no significant adverse events reports with only mild and temporary side effects, such as haematuria, experienced.
This study demonstrated that intravesical BTA can significantly improve symptoms associated with long-term indwelling catheters and may help avoid more complex and invasive interventions.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
2. Mahajan ST, Brubaker L. Botulinum toxin: From life-threatening disease to novel medical ther-apy. Am J Obstet Gynecol. 2007;196:7–15.
3. Simpson D. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl. 1997;6:S169–75.
4. Hunter KF, Bharmal A, Moore KN. Long-term bladder drainage: suprapubic catheter versus other methods: a scoping review. Neurourol Urodyn. 2013;32:944–51. doi: 10.1002/nau. 22356
5. Mahajan ST, Brubaker L. Botulinum toxin: From life-threatening disease to novel medical therapy. Am J Obstet Gynecol. 2007;196:7–15.
6. Orasanu B, Mahajan ST. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol. 2013;29(1):2–11. doi: 10.4103/0970-1591.109975
7. Saito M, Tabuchi F, Otsubo K, Miyagawa I. Treatment of overactive bladder with modified intravesical oxybutinin chloride. Neurourol Urodyn. 2000;19:683–8.
8. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. J Urol. 1997;158:2087–92.
9. Young MJ, Osman NI, Phillips L, Mangera A, Reid SV, Inman RD, Chapple CR. Another therapeutic role for intravesical botulinum toxin: patients with long-stay catheters and refractory bladder pain and catheter bypass leakage. Eur Urol Focus. 2020 Mar 15;6(2):339–343. doi: 10.1016/j.euf.2018.10.011. Epub 2018 Nov 2.
10. Elvira Lekka, Ling K. Lee, Successful treatment with intradetrusor botulinum-a toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol 2006;50(4) 2006:806–810, ISSN 0302-2838, doi: 10.1016/j. eururo.2005.12.015
11. Vaidyanathan S, Ward J, Soni BM, Hughes P, Oo T. Persistent urine leakage around a suprapubic catheter: the experience of a person with chronic tetraplegia. Spinal Cord Ser Cases. 2018 Apr 4;4:31. doi: 10.1038/s41394-018-0058-7. PMID: 29644100; PMCID: PMC5884805.